{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009766","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.062453+00:00","generated_at":"2026-06-04T22:32:59.887325+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Indaptus reports FY2023 loss of $1.83/sh; cash $13.4M; Phase 1 Decoy20 advancing","bullets":["FY2023 net loss per share $1.83 vs $1.73 in FY2022; cash at Dec 31, 2023 was $13.4M (down from $26.4M).","Cash runway expected through Q3 2024; excludes $0.3M ATM proceeds in March 2024.","Positive results from second cohort of Phase 1 Decoy20 trial; initiating multi-dose in solid tumors.","European patent approved in Jan 2024 for platform technology covering viral infection composition.","R&D expenses rose 21% YoY to $7.6M driven by Phase 1 trial and pipeline expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009766","json":"https://secwatch.observer/filing/0001493152-24-009766.json","markdown":"https://secwatch.observer/filing/0001493152-24-009766.md","text":"https://secwatch.observer/filing/0001493152-24-009766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224009766/0001493152-24-009766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224009766/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:32:59.887325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}